Continuous Quantification of Fibrosis and Associated Histological Activity Scores

FibroNest automatically quantifies the histological Phenotype of Fibrosis and the associated histological features of NASH Activity to aid the assessment of the severity and progression of NASH with continuous scores.

(Research Only Use)

~ 6 Phase 2 completed

~ 2 Phase 3 OnGoing

~ 4396 Images analysed

~ 5 GCP Audits OK'ed

~ 6 Phase 2 completed ~ 2 Phase 3 OnGoing ~ 4396 Images analysed ~ 5 GCP Audits OK'ed

FibroNest Visualizes and Quantifies the histological phenotype of Fibrosis and its associated Activity Features

Morphometry

MACRO Steatosis (L/M)

COVER - SRQ - MID HIGH TEXTURES STEAT.png

Ballooning

Architecture

Nuclear Inflammation

#0007 - PSR+ FibroNest Nuclei Texturess.png

Tissue Architecture

AUGMENTED PATHOLOGY

Localization

PSR + FIBERS+ACRHITECTURE+ HEAT CHART THRESHOLDED.png

SeptAL Bridge Severity

SQR - NASH BIOPSY + FibroNest Septal.png

TISSUE PANELS

FibroNest Continuous Scores can show effect of a compound “inside” categorical stages

Evaluation of the multivendor performance of a novel histology-based fibrosis phenotypic composite score and its correlation with NASH-CRN Fibrosis scores in patients with NASH Li Chen (1), Michael Lung (2), Cynthia Behling (3), Anthony Azzara (4), Diane Shevell (4), Arun J. Sanyal (5), Mathieu Petitjean (1) - (1) Pharmanest, Princeton, NJ, USA (2) Pacific Rim Pathology, San Diego, CA, USA (3) Department of Pediatrics University of California, San Diego, CA, USA (4) Bristol Myers Squibb, Princeton, NJ, USA (5) Virginia Commonwealth University, Richmond, VA, USA Presented at AASLD 2021, #1601 (Poster Here)

Fibrosis Phenotyping establishes clinical continuous scores to assess the severity and progression of fibrosis

Continuous staging of NASH Patients at low (F1) Fibrosis Severity: Evaluation of the performance of a novel histology-based fibrosis phenotypic composite score and predictive AI tools. Li Chen (1), Dmitry Fedorov (2), Mathieu Petitjean (1), Benjamin J. Bruno (3), Kilyoung Kim (3), Cynthia Behling (4), Anthony DelConte (5), Nachiappan Chidambaram (3) - (1) Pharmanest Inc, Princeton, New Jersey, USA (2) ViQi Inc, Santa Barbara, California, USA (3) Lipocine Inc. Salt Lake City, Utah, USA (4) Pacific Rim Pathology, San Diego, CA, USA (5) Saint Joseph’s University, Philadelphia, PA, USA - Presented at AASLD 2021, #1587 (Poster Here)

The FibroNest method contributes to the discovery of new Antifibrotic Compounds

FibroNest is validated on Adult and Pediatric NASH, +20 different animal models and on 3DNASH Spheroids

In-Vitro human 3D NASH model as a screening-based discovery approach for selecting and prioritizing drug candidates. Simon Strӧbel, Jana Rupp, Katia Fiaschetti, Agnieska Pajat, Katarzyna Sanchez (1), Mathieu M. Petitjean, Li Chen (2), Manuela Bieri, Armin Wolf, Sue Grepper Eva Thoma, Radina Kostadinova (1). (1) InSphero AG, Schlieren, Switzerland (2) PharmaNest, Princeton, NJ, USA- Presented at AASLD 2021, #1906 (Poster Here)